论文部分内容阅读
目的:观察格列美脲联合精蛋白生物合成人胰岛素注射液治疗2型糖尿病的治疗效果。方法:2型糖尿病患者54例随机分为观察组和对照组各27例。对照组于早餐及晚餐前30 min皮下注射精蛋白生物合成人胰岛素注射液,起始量0.4 u/(kg.d),按早3/5、晚2/5分配,以后根据尿糖及血糖调整剂量,维持剂量0.3 u/(kg.d)。观察组精蛋白生物合成人胰岛素注射液用法、用量同对照组,并给予格列美脲片,起始剂量为1~2 mg/次,1次/d,维持量为1~4 mg/次,1次/d,每日晨口服。2组疗程均为90 d。比较治疗前、后空腹血糖、餐后2 h血糖、糖化血红蛋白水平,血糖达标时间、低血糖发生率和精蛋白生物合成人胰岛素注射液每日用量。结果:2组治疗后空腹血糖,餐后2 h血糖,糖化血红蛋白均较治疗前下降(P<0.05),2组治疗后上述指标间比较差异有统计学意义(P<0.05)。对照组血糖达标时间(8.25±2.80)h,低血糖发生率38%,每日胰岛素用量(24.11±0.30)u;观察组血糖达标时间(6.83±3.10)h,低血糖发生率为12%,每日胰岛素用量为(17.24±0.20)u,2组比较差异有统计学意义(P<0.05)。结论:格列美脲联合精蛋白生物合成人胰岛素注射液治疗2型糖尿病疗效优于单用精蛋白生物合成人胰岛素。
Objective: To observe the effect of glimepiride combined with protamine biosynthesis human insulin injection in the treatment of type 2 diabetes mellitus. Methods: 54 patients with type 2 diabetes were randomly divided into observation group and control group, 27 cases each. The control group was subcutaneously injected with protamine biosynthesis human insulin at a dosage of 0.4 u / (kg · d) subcutaneously 30 min before breakfast and dinner. The control group was divided into two groups according to urine glucose and blood glucose Adjust the dose to maintain the dose of 0.3 u / (kg.d). Observed group protamine biosynthesis of human insulin injection usage, the same amount as the control group, and given glimepiride tablets, the initial dose of 1 ~ 2 mg / time, 1 / d, the maintenance dose of 1 ~ 4 mg / time , 1 time / d, oral morning daily. Two groups of treatment were 90 d. The fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, glycometabolism time, incidence of hypoglycemia and daily dosage of protamine biosynthesis human insulin injection were compared before and after treatment. Results: The fasting blood glucose, 2 h postprandial blood glucose and HbA1c in both groups were significantly lower than those before treatment (P <0.05). There was significant difference between the two groups after treatment (P <0.05). In the control group, the blood glucose reached the standard time (8.25 ± 2.80) h, the incidence of hypoglycemia was 38% and the daily insulin dosage (24.11 ± 0.30) u. The observation group had a blood glucose compliance time of 6.83 ± 3.10 h and a hypoglycemia rate of 12% The daily insulin dosage was (17.24 ± 0.20) u, the difference between the two groups was statistically significant (P <0.05). CONCLUSIONS: Glimeporide and protamine biosynthesis human insulin for the treatment of type 2 diabetes mellitus is superior to the use of protamine biosynthesis of human insulin.